People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

GLP-1 drugs do a lot more than just help you lose weight. They can help your heart, brain, and more, but beware what they ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9.Stay Ahead of the ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...

Medicare to negotiate prices for blockbuster drugs like Ozempic and Wegovy, potentially saving enrollees millions.

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...

BofA Securities maintained a Buy rating on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) with a price target of DKK1,075.00. The firm's analyst commented on the stock's recent performance, noting ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...